BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile

When do Bacteriostatic Sodium Chloride 0.9% In Plastic Container patents expire, and when can generic versions of Bacteriostatic Sodium Chloride 0.9% In Plastic Container launch?

Bacteriostatic Sodium Chloride 0.9% In Plastic Container is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, and Hospira. and is included in three NDAs.

The generic ingredient in BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is sodium chloride. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the sodium chloride profile page.

Summary for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	142
Clinical Trials:	49
DailyMed Link:	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alfonso X El Sabio University	Phase 1
Assistance Publique Hopitaux De Marseille	Phase 4
University of Louisville Health Care	Phase 1/Phase 2

See all BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER clinical trials

Pharmacology for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Drug Class	Osmotic Laxative
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption

US Patents and Regulatory Information for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;INJECTION	088909-002	May 15, 1985		DISCN	No	No
Hospira	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;INJECTION	018800-003	Oct 29, 1982	AP	RX	Yes	Yes
Fresenius Kabi Usa	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;INJECTION	088911-001	Feb 7, 1985	AP	RX	No	No
Abraxis Pharm	BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;INJECTION	088909-001	Feb 7, 1985		DISCN	No	No

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory for Bacteriostatic Sodium Chloride 0.9% Injection

Introduction to Bacteriostatic Sodium Chloride 0.9% Injection

Bacteriostatic Sodium Chloride 0.9% Injection is a sterile, nonpyrogenic, isotonic solution of sodium chloride in water, designed for parenteral use. It is commonly used as a vehicle for diluting or dissolving drugs prior to injection. This solution contains 9 mg of sodium chloride per milliliter and 0.9% benzyl alcohol as a bacteriostatic preservative[2][5].

Global Market Outlook for Sodium Chloride Solutions

The broader market for sodium chloride solutions, including the 0.9% sodium chloride injection, is experiencing significant growth driven by various factors.

Market Size and Growth Rate

The 0.9% Sodium Chloride Injection Market was valued at USD 13.4 billion in 2023 and is projected to reach USD 25.8 billion by 2031, growing at a CAGR of 4.3%[3].

Key Drivers of Market Growth

Increasing Demand in Healthcare

The healthcare sector is a major driver for the demand of 0.9% sodium chloride injections. These solutions are essential for maintaining fluid and electrolyte balance, especially in hospital settings. The growing need for parenteral solutions in hospitals and clinics is a significant factor contributing to market growth[3].

Pharmaceutical Applications

Sodium chloride solutions are widely used in the pharmaceutical industry as a vehicle for administering drugs. The increasing production of pharmaceuticals that require dilution or dissolution in an aqueous vehicle further boosts the demand for bacteriostatic sodium chloride injections[2][5].

Food and Beverage Industry

Although not directly related to the pharmaceutical use, the overall demand for sodium chloride in the food and beverage industry also influences the production capacity and supply chain of sodium chloride, indirectly affecting the availability and pricing of pharmaceutical-grade sodium chloride[1].

Segmentation of the Market

By Type

The market for 0.9% sodium chloride injections is segmented by volume, including 100ml, 250ml, 500ml, and other sizes. Each segment has its own demand dynamics based on the specific needs of healthcare providers and pharmaceutical manufacturers[3].

By Application

The primary applications include hospitals, clinics, and other healthcare facilities. Hospitals are the largest consumers due to the frequent need for parenteral solutions in patient care[3].

Geographical Market Analysis

North America

North America, particularly the United States, is a significant market for 0.9% sodium chloride injections. The region's advanced healthcare infrastructure and high demand for pharmaceuticals contribute to its substantial market share[1][3].

Asia-Pacific

The Asia-Pacific region, including countries like China, is also experiencing rapid growth. China's increasing investments in healthcare and pharmaceutical production are driving the demand for sodium chloride solutions in this region[1].

Competitive Landscape

The market for bacteriostatic sodium chloride injections is competitive, with several key players such as Fresenius Kabi USA, LLC, and Hospira, Inc. These companies are involved in the manufacture and distribution of these solutions, ensuring a steady supply to meet the growing demand[2][5].

Financial Trajectory

Revenue Projections

The revenue from the 0.9% sodium chloride injection market is expected to grow significantly, from USD 13.4 billion in 2023 to USD 25.8 billion by 2031. This growth is driven by the increasing demand in healthcare and pharmaceutical applications[3].

Cost and Pricing

The cost-efficiency of producing sodium chloride solutions, combined with the essential nature of these products in healthcare, influences pricing. The market is expected to maintain a balance between cost and revenue, ensuring profitability for manufacturers while keeping the product accessible to healthcare providers[3].

Challenges and Opportunities

Regulatory Compliance

Manufacturers must comply with stringent regulatory requirements to ensure the quality and safety of bacteriostatic sodium chloride injections. This compliance can be a challenge but also presents an opportunity for companies to differentiate themselves through high-quality products[2][5].

Technological Advancements

Advancements in manufacturing and packaging technologies can improve the shelf life and usability of these solutions, offering opportunities for market growth and innovation[3].

Key Takeaways

• The 0.9% sodium chloride injection market is projected to grow at a CAGR of 4.3% from 2023 to 2031.
• The market is driven by increasing demand in healthcare and pharmaceutical applications.
• North America and the Asia-Pacific region are significant markets due to their advanced healthcare infrastructure and growing pharmaceutical production.
• Key players like Fresenius Kabi USA, LLC, and Hospira, Inc. are major contributors to the market.
• Regulatory compliance and technological advancements are crucial for market growth.

FAQs

Q: What is the primary use of Bacteriostatic Sodium Chloride 0.9% Injection? A: The primary use is as a vehicle for diluting or dissolving drugs prior to parenteral injection.

Q: What is the projected market size of the 0.9% Sodium Chloride Injection Market by 2031? A: The market is expected to reach USD 25.8 billion by 2031.

Q: Which regions are significant markets for 0.9% sodium chloride injections? A: North America and the Asia-Pacific region are significant markets.

Q: What are the key drivers of the market growth for 0.9% sodium chloride injections? A: Increasing demand in healthcare and pharmaceutical applications are key drivers.

Q: Who are some of the major manufacturers of Bacteriostatic Sodium Chloride 0.9% Injection? A: Fresenius Kabi USA, LLC, and Hospira, Inc. are among the major manufacturers.

Cited Sources

1. Fact.MR, Sodium Chloride (NaCl) Market Size, Share & Trends 2034.
2. Pfizer, Bacteriostatic 0.9% Sodium Chloride Injection, USP.
3. Market Research Intellect, 0.9% Sodium Chloride Injection Market Size and Projections.
4. Research Nester, Industrial Sodium Chloride Share Size Growth & Forecast 2027.
5. DailyMed, Bacteriostatic Sodium Chloride Injection, USP.